|
|
 |
|
Viewing report
|
|
|
|
Central Nervous System - Anxiety Drug Pipeline Report
Life Science Analytics, June 2007, Pages: 23
Life Science Analytics, 'Central Nervous System - Anxiety Drug Pipeline Report' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of anxiety drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Customers who bought this item also bought
Central Nervous System Anxiety
Strategic Perspectives 2001: Social Anxiety Disorder - The Target Anxiety Market For Leading Players
Strategic Perspectives 2001: Generalized Anxiety Disorder - Driven by Effexor and Open to Expansion
Target Analytical Report - CCKBR
Sepracor Inc. - Financial and Strategic Analysis Review
H Lundbeck AS - Financial and Strategic Analysis Review
Short Protocols in Neuroscience: Systems and Behavioral Methods
Short Protocols in Neuroscience: Systems and Behavioral Method
Oxford Comprehensive Textbook of AIDS Psychiatry
Strategic Perspectives 2001: Obsessive Compulsive Disorder - A Developed Market Still Attracting New Entrants
The Top 50 Contract Research Organisations In Europe For CNS Diseases & Disorders
Strategic Perspectives 2001: Antidepressant Treatment Strategies - Efficacy Drives Psychiatrist Drug Choice
|
|
|
|
